Akero Therapeutics ( (AKRO) ) has released its Q2 earnings. Here is a breakdown of the information Akero Therapeutics presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Akero Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for serious metabolic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH). The company is headquartered in South San Francisco and is known for its lead product candidate, efruxifermin (EFX), which is currently undergoing Phase 3 clinical trials.
In its second quarter of 2025, Akero Therapeutics reported significant progress in its clinical programs, highlighted by the publication of 96-week Phase 2b SYMMETRY trial results in the New England Journal of Medicine. The company also presented compelling data at the EASL Congress 2025, demonstrating the potential of EFX to reverse cirrhosis in patients with MASH.
Key financial metrics for the quarter ending June 30, 2025, include cash and marketable securities totaling $1,086.2 million, which Akero believes will fund its operations into 2028. The company reported increased research and development expenses of $69.3 million, reflecting ongoing Phase 3 trials and related activities. General and administrative expenses also rose to $11.6 million, contributing to a total operating expense of $80.9 million for the quarter.
Strategically, Akero is advancing its SYNCHRONY Phase 3 program, with preliminary results expected in 2026 and 2027. The company’s efforts are focused on addressing the unmet needs of patients with MASH, a condition with no approved treatments and significant health risks.
Looking forward, Akero Therapeutics remains committed to its mission of developing transformative therapies for metabolic diseases. The company anticipates continued progress in its clinical trials and aims to leverage its strong financial position to support its strategic objectives.